merck springworks - Search News

News

Merck KGaA to Buy US Drugmaker Springworks

Merck KGaA’s $3.9 Billion Springworks Deal to Boost US Presence

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in the country.

Reuters on MSN · 4h

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

Yahoo Finance · 6h

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The acquisition price translates to an equity value of around $3.

Fierce Pharma7h

Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

49m

Stamford-based drug developer for rare cancers and tumors sold for $3.9 billion to German company

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

BioWorld22h

Shock value: Merck’s $3.9B Springworks grab provides jolt

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity ...

Devdiscourse4h

Merck's Strategic $3.9 Billion Move: A Boon for Rare Cancer Therapies

Germany's Merck KGaA will acquire US biotech firm SpringWorks Therapeutics for $3.9 billion. This strategic move aims to ...

16h

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results